We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs.
- Authors
Gobbi, P. G.; Valentino, F.; Lambelet, P.; Perfetti, V.; Bergamaschi, G.; Girino, M.; Corazza, G. R.
- Abstract
There is great interest in chemotherapies for relapsed or refractory lymphomas that are both directly effective against the lymphoma and able to mobilize PBSCs for rescue after high-dose chemotherapy (HDC). Twenty-eight patients with relapsed or refractory lymphomas were treated with a shortened, intensified MJMA regimen (mitoxantrone 10 mg/m2 i.v. day 1, carboplatin 200 mg/m2 i.v. days 1–2, methylprednisolone 500 mg/m2 i.v. days 1–3, cytarabine 2000 mg/m2 i.v. day 3) for six cycles every 21 days. A median of five cycles/patient was administered. Nineteen patients had complete responses, seven partial responses and two no responses. The only remarkable toxicity was hematological. In 18 patients who were candidates for HDC, a mean of 10.45 × 106 CD34/kg of patients' body weight was collected (range: 3.70–24.88 × 106/kg). Eleven patients underwent transplantation, which converted two of four partial responses into complete responses. The median follow-up was 49 months. Survival parameters were not related to relapsed/refractory status or to the time from the last chemotherapy, but were related only weakly to the number of prior chemotherapies. Outpatient MJMA is a feasible and very effective salvage chemotherapy per se. The complete response rate is high and it is a powerful PBSC mobilizer.Bone Marrow Transplantation (2009) 44, 19–25; doi:10.1038/bmt.2008.421; published online 12 January 2009
- Subjects
DRUG therapy; LYMPHOPROLIFERATIVE disorders; LYMPHOMAS; DISEASE relapse; BONE marrow transplantation
- Publication
Bone Marrow Transplantation, 2009, Vol 44, Issue 1, p19
- ISSN
0268-3369
- Publication type
Article
- DOI
10.1038/bmt.2008.421